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Abstract: Antithymocyte globulin (ATG) is used in the prevention of graft-versus-host disease during
allogeneic hematopoietic stem cell transplantation. It is generally accepted that ATG mediates its
immunosuppressive effect primarily via depletion of T cells. Here, we analyzed the impact of
ATG-Fresenius (now Grafalon®) on human monocyte-derived dendritic cells (DC). ATG induced
a semi-mature phenotype in DC with significantly reduced expression of CD14, increased expression
of HLA-DR, and intermediate expression of CD54, CD80, CD83, and CD86. ATG-DC showed
an increase in IL-10 secretion but no IL-12 production. In line with this tolerogenic phenotype,
ATG caused a significant induction of indoleamine 2,3-dioxygenase expression and a concomitant
increase in levels of tryptophan metabolites in the supernatants of DC. Further, ATG-DC did not
induce the proliferation of allogeneic T cells in a mixed lymphocyte reaction but actively suppressed
the T cell proliferation induced by mature DC. These data suggest that besides its well-known
effect on T cells, ATG modulates the phenotype of DC in a tolerogenic way, which might constitute
an essential part of its immunosuppressive action in vivo.
Keywords: allogeneic hematopoietic stem cell transplantation; dendritic cell; antithymocyte globulin;
Grafalon; tolerogenic; indoleamine 2,3-dioxygenase; immunosuppressive
1. Introduction
Allogeneic hematopoietic stem cell transplantation (aHSCT) is one of the most effective treatments
for hematologic malignancies. However, graft-versus-host disease (GvHD) is still the major cause of
mortality in aHSCT [1].
Dendritic cells (DC) play a crucial role in the pathogenesis of GvHD. But aside from their ability
to induce GvHD, DC can also exhibit tolerogenic properties that may be exploited in the prevention
and treatment of GvHD [1]. Tolerogenic DC are characterized by a semi-mature phenotype with high
expression of MHC II (major histocompatibility complex) and low expression of costimulatory B7
molecules. They mainly secrete immunosuppressive mediators, such as IL-10, and lack the production
of proinflammatory cytokines such as IL-12 [2].
Immunosuppressive medication of patients undergoing aHSCT includes antithymocyte globulin
(ATG)-Fresenius (now Grafalon®), a polyclonal antibody-mixture raised in rabbits against the human
lymphoblastic T cell line Jurkat [3]. Administration of ATG leads to the depletion of T lymphocytes [4].
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ATG also affects other immune cells, including dendritic cells (DC) [4], as it directly binds to different
DC surface antigens such as CD1a, CD80, CD86, CD206, and HLA-DR [5,6]. Furthermore, ATG induces
different signaling pathways in DC, e.g., the activation of the protein kinases ERK1/2 and p38, as well
as NF-κB signaling [6], and depletes circulating DC [7]. However, since host-derived tissue-resident
DC subsets persist over a prolonged period after aHSCT [8], the effects of ATG on DC probably
exceed depletion. And indeed, ATG interferes with various aspects of DC function: it modulates
DC differentiation, inhibits maturation induced by different stimuli, suppresses the IL-12 secretion
of mature DC, and reduces the ability of mature DC to stimulate T cells. Furthermore, it seems to
induce a tolerogenic phenotype accompanied by mRNA expression of indoleamine 2,3-dioxygenase
(IDO) [5,6,9,10]. In patients with ATG prophylaxis, we previously reported systemic release of
tryptophan metabolites on the day of aHSCT also indicating activation of IDO by ATG [11].
IDO catalyzes the initial step of the tryptophan metabolism [12]. Its expression is a characteristic
of tolerogenic DC and is associated with enhanced tryptophan degradation [13]. Both the deprivation
of tryptophan and the accumulation of tryptophan metabolites represent potent immune-regulatory
mechanisms [14,15]. Additionally, IDO-expressing DC are able to induce regulatory T cells [14] and
contribute to renal allograft tolerance in mice [16].
Since published studies on the effect of ATG on human DC were conducted with different
ATG preparations and experimental settings [5,6,9,10], we chose ATG-Fresenius, which is approved
for GvHD prophylaxis and had the strongest effect on the release of tryptophan metabolites in
patients [11], and studied the effect of ATG on immature DC in the absence of any maturation stimulus.
This setting reflects the clinical situation where patients receive ATG prior to aHSCT and tissue-resident
immature DC encounter ATG. ATG induced a tolerogenic DC phenotype with increased expression
of IDO and an increased tryptophan metabolism. In accordance with their tolerogenic phenotype,
ATG-DC negatively influenced the T cell proliferation induced by LPS-matured DC. These results
clearly demonstrate that ATG is a potent tolerogenic stimulus for DC. They also suggest that the
mechanism underlying the clinical effects of ATG on graft rejection and GvHD might go far beyond
T lymphocyte depletion.
2. Results
2.1. ATG Induces a Semi-Mature Phenotype in DC
To investigate the influence of ATG on the maturation of DC, we cultivated monocyte-derived DC
with or without LPS (10 ng/mL) or with a therapeutically relevant concentration of ATG-Fresenius
(100 µg/mL) (now Grafalon®) [3]. In addition, we incubated DC with Alemtuzumab (100 µg/mL),
another immunosuppressive drug directed against lymphocytes that is approved for the prevention of
GvHD [17]. After 48 h we analyzed the expression of CD1a, CD11c, CD14, CD54, DC-SIGN (CD209),
HLA-DR, CD80, CD83, and CD86. LPS induced a fully mature DC phenotype with significantly
increased expression of HLA-DR, low expression of CD14, and high expression of CD54, CD80, CD83,
and CD86 (Figure 1A–F, Figure S2).
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Figure 1. Antithymocyte globulin (ATG) induces a semi-mature dendritic cells (DC) phenotype. 
Monocyte-derived DC were stimulated with or without LPS (10 ng/mL), ATG (100 µg/mL), 
Alemtuzumab (Alem; 100 µg/mL) (A–G), or polyclonal rabbit IgG (100 µg/mL) (H,I); (A–G) After 48 
h, cells were harvested, washed, and stained with fluorochrome-conjugated monoclonal antibodies 
against CD14 (A); CD54 (B); HLA-DR (C); CD80 (D); CD83 (E); CD86 (F) and CD1a (G). Samples 
were analyzed by flow cytometry. Shown is the mean of the median fluorescence intensity (MFI) 
(isotype subtracted) relative to unstimulated DC ± SEM (n = 3); (H,I) After 24 h, the supernatants 
were harvested and the amounts of IL-10, IL-12, IL-6, and TNF were determined by ELISA. Data are 
means ± SEM (n ≥ 3). Statistical analysis was performed with one-way ANOVA (* p ≤ 0.05, ** p ≤ 0.01, 
*** p ≤ 0.001) (n.s.: not significant). 
ATG induced a semi-mature DC phenotype characterized by significantly reduced CD14 and 
increased HLA-DR expression. Furthermore, ATG slightly increased CD80, CD83, CD86, and CD54 
expression. Alemtuzumab did not affect the expression of the investigated surface markers. The 
expression of CD1a (Figures 1G and S2), CD11c, and DC-SIGN (Figure S1A,B) was not changed by 
any of the applied stimuli. 
To study whether stimulatory pathways are still functional in ATG-treated DC, we stimulated 
monocyte-derived DC either with ATG for 48 h or incubated them for the same time without 
stimulation. After 48 h, cells received LPS stimulation for another 48 h. Finally, DC surface markers 
were analyzed by means of flow cytometry (Figure S3). With the exception of CD83, which was 
slightly, but not significantly lower expressed in DC with preceding ATG-treatment, the levels of the 
other analyzed DC markers (HLA-DR, CD80, CD86, CD1a) were comparable between cells with and 
without ATG treatment.  
2.2. ATG Induces IL-10 Secretion in DC 
Next, we analyzed the effect of ATG on cytokine secretion by DC. Since ATG is a polyclonal 
preparation of rabbit IgG antibodies against human T lymphoblasts [3], we used normal polyclonal 
rabbit IgG as a control. LPS-DC produced large amounts of IL-10, IL-12, IL-6, and TNF. In contrast, 
ATG induced IL-10 but no IL-12, a typical feature of tolerogenic DC (Figure 1H,I). Furthermore, 
ATG-stimulated DC were only weak producers of IL-6 but secreted TNF. Neither ATG nor the IgG 
control influenced the investigated cytokines in monocytes, while LPS strongly induced their 
expression (Figure S4). 
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Figure 1. Antithymocyte globulin (ATG) induces a semi-mature dendritic cells (DC) phenotype.
Monocyte-derived DC were stimulated with or without LPS (10 ng/mL), ATG (100 µg/mL),
Alemtuzumab (Alem; 100 µg/mL) (A–G), or polyclonal rabbit IgG (100 µg/mL) (H,I); (A–G) After
48 h, cells were harvested, washed, and stained with fluorochrome-conjugated monoclonal antibodies
against CD14 (A); CD54 (B); HLA-DR (C); CD80 (D); CD83 (E); CD86 (F) and CD1a (G). Samples
were analyzed by flow cytometry. Shown is the mean of the median fluorescence intensity (MFI)
(isotype subtracted) relative to unstimulated DC ± SEM (n = 3); (H,I) After 24 h, the supernatants
were harvested and the amounts of IL-10, IL-12, IL-6, and TNF were determined by ELISA. Data are
means ± SEM (n≥ 3). Statistical analysis was performed with one-way ANOVA (* p≤ 0.05, ** p ≤ 0.01,
*** p ≤ 0.001) (n.s.: not significant).
ATG induced a semi-mature DC phenotype characterized by significantly reduced CD14
and increased HLA-DR expression. Furthermore, ATG slightly increased CD80, CD83, CD86,
and CD54 expression. Alemtuzumab did not affect the expression of the investigated surface markers.
The expression of CD1a (Figure 1G and Figure S2), CD11c, and DC-SIGN (Figure S1A,B) was not
changed by any of the applied stimuli.
To study whether stimulatory pathways are still functional in ATG-treated DC, we stimulated
monocyte-derived DC either with ATG for 48 h or incubated them for the same time without
stimulation. After 48 h, cells received LPS stimulation for another 48 h. Finally, D surface markers
were analyzed by means of flow cytometry (Figure S3). With the exception of CD83, which was slightly,
but not significantly low r expressed in C with preceding ATG-treatment, the l vels of the other
analyzed DC markers (HLA-DR, CD80, CD86, CD1a) were comparable between cells with and without
ATG treatment.
2.2. ATG Induces IL-10 Secretion in DC
Next, we analyzed the effect of ATG on cytokine secretion by DC. Since ATG is a polyclonal
preparation of rabbit IgG antibodies against human T lymphoblasts [3], we used normal polyclonal
rabbit IgG as a control. LPS-DC produced large amounts of IL-10, IL-12, IL-6, and TNF. In contrast,
ATG induced IL-10 but no IL-12, typical feature of tolerogenic DC (Figure 1H,I). Furthermore,
ATG-stimulat d DC were only w ak pr ducers of IL-6 but secret d TNF. Neither ATG nor the
IgG control infl enced the investigated cytokines in monocytes, while LPS strongly induced their
expression (Figure S4).
2.3. ATG Induces mRNA Expression of IDO in DC
In order to investigate whether the tolerogenic phenotype of ATG-DC is accompanied by the
expression of IDO, we analyzed mRNA expression of IDO1 and IDO2 after incubation with or without
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LPS (10 ng/mL), ATG (100 µg/mL), or the corresponding IgG control (100 µg/mL). After 4 h of
incubation, LPS significantly enhanced the expression of IDO1 and IDO2 (Figure 2A,B).
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Figure 2. ATG induces IDO in DC at the mRNA and protein level. Monocyte-derived DC were
cultivated with or without LPS (10 ng/mL), ATG (100 µg/mL), and IgG isotype control (100 µg/mL),
respectively. (A–D) After 4 h and 24 h, mRNA expression of IDO1 (A,C) and IDO2 (B,D) was analyzed
by means of quantitative real-time PCR relative to 18S rRNA expression. Data are means± SEM (n≥ 3);
(E) After 48 h, Western blot analysis was performed using antibodies against IDO and β-actin. Shown
is one representative out of five i dependent experiments; (F) Densitometric analysis of five different
experimen s (normalized to t LPS sign l). Data are means ± SEM; (G) Cells w re harvested after
48 h, washed, and staine with Alexa Fluor (AF) 488-conjugated monoclonal anti-IDO antibody and
the suitable isotype. Shown is a dot blot of the respective cell populations and overlaid histograms of
the isotype (grey) and the anti-IDO antibody (black) of one representative of six experiments. Numbers
indicate the median fluorescence of IDO, bold numbers in the lower right corner indicate the difference
median fluorescence IDO—median fluorescence isotype. Statistical analysis was performed using
one-way ANOVA (* p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001).
After 24 h, both LPS and ATG strongly increased the expression of IDO1 and IDO2 (Figure 2C,D).
In contrast to DC, ATG exerted no significant impact on IDO1 or IDO2 expression in monocytes
(Figure S5A,B). Besides IDO, ATG and LPS also significantly increased the mRNA expression of the
gene KYNU coding for kynureninase, another enzyme of the kynurenine pathway (Figure S5C). Since
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kynurenine is discussed as a ligand of the aryl hydrocarbon receptor (AHR) [18], we also investigated
expression of this receptor. DC constitutively expressed AHR mRNA, but neither ATG nor LPS affected
its expression (data not shown).
2.4. ATG Induces IDO at the Protein Level
To quantify IDO at the protein level, monocyte-derived DC were cultured for 48 h with or without
LPS (10 ng/mL), ATG (100 µg/mL), or the IgG isotype control (100 µg/mL). In accordance with the
mRNA expression data, Western blot analysis revealed a clear induction of IDO protein expression
in DC by ATG (Figure 2E,F). Furthermore, we performed intracellular staining of IDO in DC and
confirmed the Western blot results by means of flow cytometry (Figure 2G). In line with the mRNA
data, ATG did not affect IDO expression in monocytes (data not shown).
2.5. ATG Stimulates Tryptophan Metabolism
To test whether the increased expression of IDO in response to ATG affected the production of
kynurenines, we cultured monocyte-derived DC with or without LPS (10 ng/mL) or ATG (100 µg/mL)
for 48 h and analyzed the levels of tryptophan and selected kynurenines in DC culture supernatants
by means of LC-MS/MS. We detected significantly decreased tryptophan levels in the supernatants of
DC stimulated with LPS or ATG, indicating that increased IDO expression indeed led to enhanced
degradation of tryptophan (Figure 3A).
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Figure 3. ATG enhances the tryptophan metabolism. Monocyte-derived DC were incubated for 48 h
with or without LPS (10 ng/mL) or ATG (100 µg/mL). After 48 h, supernatants were harvested and
levels of tryptophan (A); kynurenine (B); anthranilic acid (C); 3-hydroxyanthranilic acid (D); quinolinic
acid (E) and kynurenic acid (F) were measured by means of liquid chromatography-electrospray
ionization-tandem mass spectrometry (LC-ESI-MS/MS). Data are means ± SEM (n = 6) of the
concentration of the respective metabolites (µM) relative to the unstimulated control. Statistical
analysis was performed with one-way ANOVA (* p ≤ 0.05, *** p ≤ 0.001) (n.s.: not significant).
Furthermore, LPS significantly incr ls f the kynurenine pathway intermediates
kynureni e, anthranilic a i kynurenic acid, but not the evels of 3-hydroxy thr nilic acid
and quinolinic acid (Figure 3B–F). ATG slightly nhanc d the levels of the analyzed kynurenine
pathway intermediates.
2.6. ATG-Stimulated DC Suppress the Proliferation of Allogeneic T Cells
To determine the T cell stimulatory capacity of ATG-stimulated DC, we incubated
monocyte-derived DC with or without LPS (10 ng/mL), ATG (100 µg/mL), and IgG isotype control,
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respectively, for 48 h. Next, we co-cultured different numbers of these DC for 5 days with allogeneic
T cells in the absence of LPS, ATG, or IgG control, and analyzed proliferation of the co-cultures by means
of a [3H]-thymidine proliferation assay. LPS-DC strongly induced proliferation of T lymphocytes.
However, neither ATG-DC (Figure 4A) nor IgG control (data not shown) induced T cell proliferation.
Int. J. Mol. Sci. 2016, 17, 2081 6 of 11 
 
2.6. ATG-Stimulated DC Suppress the Proliferation of Allogeneic T Cells 
To determine the T cell stimulatory capacity of ATG-stimulated DC, we incubated 
monocyte-derived DC with or without LPS (10 ng/mL), ATG (100 µg/mL), and IgG isotype control, 
respectively, for 48 h. Next, we co-cultured different numbers of these DC for 5 days with allogeneic 
T cells in the absence of LPS, ATG, or IgG control, and analyzed proliferation of the co-cultures by 
means of a [3H]-thymidine proliferation assay. LPS-DC strongly induced proliferation of T 
lymphocytes. However, neither ATG-DC (Figure 4A) nor IgG control (data not shown) induced T 
cell proliferation. 
Figure 4. Reduced proliferation of allogeneic T cells in the presence of ATG-DC. Monocyte 
derived-DC were stimulated for 48 h with or without LPS (10 ng/mL) or ATG (100 µg/mL). Cells 
were harvested and washed. (A) Different numbers of DC (5000, 2500, 1250, 625) were cocultured 
with allogeneic T lymphocytes in the absence of ATG or LPS; (B) LPS-matured DC were mixed 1:1 
either with immature DC (iDC) or ATG-DC. Different numbers (5000, 2500, 1250, 625) of mixed DC 
were cocultured with allogeneic T lymphocytes in the absence of ATG or LPS; (A,B) After five days, 
the proliferation rate of T cells was quantified by means of [3H]-thymidine assay. Data are means ± 
SEM (n = 4). Statistical analysis was performed using one-way ANOVA (A) or Student’s t-test (B) (* p 
≤ 0.05). 
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Figure 4. Reduced proliferation of allogeneic T cells in the presence of ATG-DC. Monocyte derived-DC
were stimulated for 48 h with or without LPS (10 ng/mL) or ATG (100 µg/mL). Cells were harvested
and washed. (A) Different numbers of DC (5000, 2500, 1250, 625) were cocultured with allogeneic
T lymphocytes in the absence of ATG or LPS; (B) LPS-matured DC were mixed 1:1 either with immature
DC (iDC) or ATG-DC. Different numbers (5000, 2500, 1250, 625) of mixed DC were cocultured with
allogeneic T lymphocytes in the absence of ATG or LPS; (A,B) After five days, the proliferation rate of
T cells was quantified by means of [3H]-thymidine assay. Data are means ± SEM (n = 4). Statistical
analysis was performed using one-way ANOVA (A) or Student’s t-test (B) (* p ≤ 0.05).
Finally, we mixed LPS-matured DC with ATG-DC or immature DC, respectively, at a ratio of 1:1,
and co-cultured the mixtures with allogeneic T lymphocytes in the absence of LPS or ATG. In this
setting, a reduced proliferation of allogeneic T cells was observed (Figure 4B and Figure S6). This effect
was significant for three out of four DC concentrations. The IgG isotype control had no effect on the
proliferation of T cells (data not sho n).
To study the possible mechanisms underlying the interaction of ATG-DC with T cells, we analyzed
the expression of T cell-inhibitory molecules on the surface of ATG-DC. We detected a lower level
of PD-L1 expression on ATG-DC compared to LPS-DC, and a higher level of TIM-3 expression on
ATG-DC compared to LPS-DC (Figure S7).
3. Discussion
There is broad consensus that the depletion of T cells is ainly responsible for the
immunosuppressive effect of T [4]. ATG is also known to induce regulatory T cells [19].
Further ore, T has been reported to bind to neutrophils, onocytes, and DC, to interact with
various surface antigens, and to influence the biology of DC [5,6,9,10,20]. However, these studies used
diff rent ATG preparations, each with a unique polyclonal mixture of IgG antibodies [4], with varying
binding capacities [5,20]. Furthermo e, the experimental setting differe . Since we aimed to mimic
the en ounter of immature (tissue-resident) DC with ATG, e chose the in ubation of imm ure DC
with ATG-Fresenius as our xperimental s tting.
As a j [ ] had detected the induction of apoptosis n immature and mature DC by
10 and 100 µg/mL ATG-Fr senius, respectively, we d termined cell count in our iDC cultures in
response to 2 days of incubation with 100 µg/mL ATG, a concentration reached in vi o in patients [3],
and detect d no difference compared to the contr l without ATG (data not shown).
ATG generated DC with significantly reduced expression of CD14, enhanced expression of
HLA-DR, and slightly increased expression of CD54, CD80, CD83, and CD86. This implies that
ATG does not induce a fully mature, but rather a semi-mature DC phenotype, which is a typical
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feature of tolerogenic DC [2]. Our data are in line with data from Leitner et al. [5], who detected
increased expression of CD83 and CD86 in response to incubation of immature DC with ATG-Fresenius.
Gillet-Hladky et al. [10] also analyzed the surface antigen expression of DC in response to ATG.
However, they used a different ATG preparation and incubated the cells simultaneously with ATG
and LPS. Therefore, their results cannot be compared.
In further experiments, we tested the ability of ATG-DC to react to subsequent LPS stimulation
and detected no differences in the expression of surface markers compared to DC stimulated only with
LPS. This indicates that the phenotype induced by ATG is reversible and that ATG-DC maintain their
reactivity towards TLR4 ligands.
In line with the semi-mature phenotype, we found ATG-DC to produce IL-10, and no IL-12.
Further, ATG-DC produced only a small quantity of IL-6. In contrast to these findings, TNF production
was clearly detectable in the presence of ATG. This seems to be contradictory to a tolerogenic phenotype
since TNF is widely known as a pro-inflammatory cytokine. However, TNF has also been used to
expand human regulatory T cells and to fortify their suppressive capacity in vitro [21]. The high
content of TNF in the serum of mice suffering from acute GvHD has consistently been demonstrated
to selectively activate regulatory T cells [22]. Since the application of ATG is accompanied by the
induction of regulatory T cells with strong suppressive capacity in vitro and in vivo [23,24], the TNF
secretion by our ATG-DC might support this enrichment of regulatory T cells after ATG administration
in patients.
The effect of ATG on cytokine secretion was specific for DC, because we could not detect any effect
on cytokine secretion by monocytes. In contrast to our results, Leitner et al. [5] reported immature DC
to secrete TNF, but not IL-10, IL-1β, and IL-6 in response to incubation with ATG. However, since these
authors did not show any data on TNF and IL-6, one cannot tell whether the amounts of TNF and
IL-6 secreted by their ATG-DC are in the range of the amounts secreted by our ATG-DC. Since they
detected about 500 times less IL-10 in the supernatant of LPS-stimulated DC than we did, one has to
consider the possibility that the different results obtained for IL-10 secretion might be due to technical
rather than biological reasons.
The expression of IDO, which catalyzes the initial and rate-limiting step of the kynurenine
pathway, is known to mediate the immunosuppressive effect of tolerogenic DC, such as inhibiting
T cell functions, activating regulatory T cells, and suppressing natural killer cells [13]. In our hands,
ATG induced the expression of IDO at both the mRNA and the protein level. Our data are in accordance
with Leitner et al. [5], who detected increased IDO mRNA expression after incubation of iDC with
ATG. Interestingly, Gillet-Hladky et al. [10], who tested the influence of a different ATG preparation
on the differentiation of DC, also found increased mRNA expression of IDO in DC. This indicates
that the effects of ATG on IDO are not restricted to a certain type of ATG preparation or phase of
DC development.
In concordance with the expression of IDO, we detected enhanced depletion of tryptophan
and slightly increased levels of kynurenine pathway intermediates in the culture supernatants of
ATG-DC. Both the formation of these metabolites and the depletion of tryptophan are known to
have immunoregulatory effects [12]. In mice, kynurenine has been identified as a ligand of the aryl
hydrocarbon receptor (AHR) [18] and the interaction of kynurenine with AHR has been demonstrated
to induce the expression of IDO [25]. Since we detected constitutive AHR mRNA expression in DC,
the interaction of kynurenine with AHR might represent a feedback loop fortifying the expression of
IDO in the presence of ATG.
Interestingly, our previous analysis of urinary levels of tryptophan metabolites in patients
undergoing aHSCT revealed marked increases in the levels of kynurenine and quinolinic acid in
response to the administration of ATG [11]. Together with the findings of the present publication,
these data strongly suggest that the influence of ATG on tryptophan metabolism in DC (and possibly
other cell types) is responsible for the ATG-induced rise in tryptophan metabolites in the urine of
aHSCT patients.
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ATG-DC did not induce the proliferation of allogeneic T cells. Similar results were obtained
by Monti et al. [9] who reported that the preincubation of immature DC with ATG has no effect on
their capacity to stimulate allogeneic T cell proliferation. However, since they used a different ATG
preparation, the comparability of the results is limited. Naujokat et al. also investigated the role of
ATG-Fresenius in an allogeneic MLR, but they tested its effect on proliferation induced by mature
DC, an experimental setting different from ours [6]. However, our ATG-DC were not only unable
to activate allogeneic T cells but when we mixed them with potent stimulatory LPS-matured DC,
ATG-DC suppressed the proliferation of allogeneic T cells.
Tolerogenic DC can limit T cell proliferation through various mechanisms. Low expression of
(co-)stimulatory molecules, low IL-12 and high IL-10 production, and/or high IDO expression can
induce regulatory T cells which in turn suppress proliferation [2]. ATG-DC have these characteristics,
but they suppress proliferation in a co-culture with potent LPS-DCs which express high levels of
co-stimulatory molecules, secrete high levels of IL-12, and express higher IDO levels as compared to
ATG-DCs. Therefore, it is unlikely that the above mentioned factors are responsible for the limited
proliferation in our experimental setting. More likely ATG-DC directly inhibit T cell proliferation,
e.g., via expression of inhibitory receptors such as PD-L1 or TIM-3. Indeed, we detected a higher
level of TIM-3 expression on ATG-DC compared to LPS-DC. Besides its direct effects on DC [26],
expression of TIM-3 on lymphoma endothelial cells has been shown to suppress the activation of CD4+
T cells [27]. Therefore, the TIM-3 expression on ATG-DC might represent a mechanism for a direct
negative interaction between DC and T cells.
4. Material and Methods
4.1. Chemicals
Unless otherwise indicated, chemicals were purchased from Sigma-Aldrich (Munich, Germany).
4.2. Isolation of Monocytes and T Lymphocytes
With approval from the local ethics committee, monocytes and T lymphocytes were isolated from
healthy donors as described previously [28].
4.3. Culture of Monocytes and Monocyte-Derived DC
Monocytes were cultured at a density of 0.5 to 1.0 × 106/mL in RPMI-1640 (Gibco, Karlsruhe,
Germany) supplemented with 2% human AB serum (PAN Biotech, Aidenbach, Germany), L-glutamine
(2 mmol/L), penicillin (50 U/mL), and streptomycin (50 mg/mL; all from Life Technologies, Karlsruhe,
Germany). For differentiation into DC, 0.5 to 1.0 × 106 monocytes/mL were cultured for six days in
medium as described above, supplemented with 10% fetal calf serum (PAN Biotech), IL-4 (144 U/mL),
and granulocyte macrophage colony-stimulating factor (GM-CSF, 225 U/mL; both from PeproTech,
Hamburg, Germany). Monocytes and DC were incubated for 4 h, 24 h, and 48 h, respectively,
with or without LPS (from Salmonella abortus equi S-form, Enzo Life Sciences, Lörrach, Germany),
ATG (Fresenius, Bad Homburg, Germany) (now named Grafalon®, distributed by Neovii Biotech,
Gräfelfing, Germany) (100 µg/mL), IgG isotype control (polyclonal, rabbit, Molecular Innovations,
Novi, MI, USA) (100 µg/mL) or Alemtuzumab (monoclonal, human, anti-CD52, Genzyme, Cambridge,
MA, USA) (100 µg/mL).
4.4. Determination of Cytokines
Determination of cytokines in culture supernatants was performed using ELISA kits from R&D
Systems (Minneapolis, MN, USA).
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4.5. Preparation of RNA, Reverse Transcription, and Quantitative Real-Time PCR
Total cellular RNA was extracted using the RNeasy Mini Kit (Qiagen, Hilden, Germany). RNA
concentration was measured using a NanoDrop Spectrophotometer (Thermo Fisher Scientific, Schwerte,
Germany). Reverse transcription was performed as described previously [29]. Primer sequences
(all from Eurofins MWG Operon, Ebersberg, Germany) are provided in Table S1.
4.6. Preparation of Whole Cell Lysates and Western Blotting
Whole cell lysates were prepared using RIPA buffer (Sigma-Aldrich) and quantified with DC
Protein Assay (Bio-Rad Laboratories, Hercules, CA, USA). After blotting, proteins were detected using
the antibodies listed in Table S2. Densitometric analyses were performed using the ChemiDoc MP
Imaging System and Image LabTM software (both Bio-Rad Laboratories).
4.7. Analysis of Tryptophan Metabolites
Culture supernatants were stored at −20 ◦C until liquid chromatography-electrospray
ionization-tandem mass spectrometry (LC-ESI-MS/MS) of tryptophan, kynurenine, anthranilic acid,
3-hydroxyanthranilic acid, quinolinic acid, and kynurenic acid, according to published protocols [30].
4.8. Flow Cytometry Analysis
Cells were washed twice with cold PBS (Gibco, Karlsruhe, Germany) containing 0.1% sodium
azide and 0.6 mg/mL immunoglobulin, and were stained with the monoclonal antibodies listed in
Table S3. For intracellular staining, the Fixation & Permeabilization Buffer Kit was used (R&D Systems).
Data were recorded on a FACS Calibur cytometer and analyzed using CellQuestPro (both BD,
Heidelberg, Germany) and FlowJo (Tree Star, Ashland, OR, USA).
4.9. Mixed Lymphocyte Reaction (MLR) and 3H-Thymidine Assay
Different numbers of DC were cocultured with 100,000 allogeneic T lymphocytes in RPMI
containing 5% AB serum, L-glutamine (2 mmol/L), penicillin (50 U/mL), and streptomycin (50 mg/mL;
all from Life Technologies). On day 5, 0.5 µCi/0.2 mL [3H]-thymidine (Amersham Pharmacia,
Piscataway, NJ, USA) was added. Incorporated radioactivity was quantified after 24 h by means
of a beta counter (Perkin Elmer, Gaithersburg, MD, USA).
4.10. Statistical Analysis
Statistical analysis was performed with one-way ANOVA or Student’s t-test using Graph Pad
Prism 5 software (GraphPad Software, La Jolla, CA, USA). A value of p < 0.05 was considered
statistically significant.
5. Conclusions
Our findings support the growing body of evidence on the effects of ATG on immune cells
other than T cells, and clearly show that ATG-Fresenius induces a tolerogenic phenotype in human
monocyte-derived DC that potently exerts its regulatory effects in an allogeneic in vitro-setting.
Interestingly, recent work shows that ATG directly induces regulatory T cells in vivo [24]. The induction
of tolerogenic DC by ATG might be a mechanism supporting the establishment of this T cell population,
which is beneficial in the context of aHSCT [31]. The findings described in the current work are focused
on the in vitro-analysis of an isolated cell population. However, ATG is known to affect various
immune cell types in vivo [4]. This complex interplay between different immune cell populations and
ATG should be carefully investigated in vivo in further studies.
In summary, our data together with published data suggest that the beneficial effect of ATG in
transplantation patients is not only the result of its T cell-depleting activity but may also be caused by
its tolerogenic “side effects”, namely direct induction of regulatory T cells and tolerogenic DC.
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